ProCE Banner Activity

Protocol 011 at Wk 144: Islatravir + Doravirine in Treatment-Naive Persons With HIV

Slideset Download
Conference Coverage
In the phase IIb trial, continued high rates of efficacy were seen in the combined ISL plus DOR arm at 144 Weeks; no participants in this arm met criteria for resistance testing.

Released: November 03, 2021

Expiration: November 02, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

ViiV Healthcare